Ascendis Pharma A (ASND) Non-Current Debt (2021 - 2026)

Ascendis Pharma A has reported Non-Current Debt for 5 years, with the latest figure at $448.5 million in Q4 2025.

• Quarterly Non-Current Debt rose 14.95% year-over-year to $448.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $448.5 million (up 14.95% YoY) and the FY2025 annual result came in at $448.5 million, up 14.95% from the prior year.
• Non-Current Debt improved to $448.5 million in Q4 2025 per ASND's latest filing, from $387.4 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $598.2 million in Q3 2023 and troughed at $112.1 million in Q4 2021.
• A 5-year average of $400.4 million and a median of $390.1 million in 2024 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2022 and 2024: Non-Current Debt soared 252.82% in 2022, then tumbled 54.81% in 2024.
• Over 5 years, Non-Current Debt stood at $112.1 million in 2021, then jumped by 252.82% to $395.4 million in 2022, then sank by 39.32% to $239.9 million in 2023, then jumped by 62.6% to $390.1 million in 2024, then advanced by 14.95% to $448.5 million in 2025.
• According to Business Quant data, Non-Current Debt over the past three periods registered $448.5 million, $387.4 million, and $373.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.